Acute Nonparalytic Poliomyelitis C0152998
A non-paralytic form of polio affecting the nervous system. Most people recover fully with rest and supportive care.
Key facts at a glance
- ICD-10
- A80.4
- ICD-11
- 1A00.0
- Body system
- infectious
- Severity
- mild
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Fever or malaise
(infectious)Mild symptoms that may not significantly impact daily life.
Frequency: Varies
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Antimicrobial or antiviral therapy
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Supportive Pain Management
Analgesics such as acetaminophen or NSAIDs may be recommended to manage muscle pain and fever associated with acute nonparalytic poliomyelitis. Treatment focuses on relieving symptoms while the immune system fights the poliovirus.
Bed Rest and Activity Modification
Adequate rest is essential during the acute phase to reduce muscle strain and prevent complications. Gradual return to normal activities should be guided by symptom improvement and healthcare provider recommendations.
Additional treatment options
Gentle Range of Motion Exercises
Once acute symptoms subside, gentle stretching and range of motion exercises help maintain muscle function and prevent stiffness. Physical therapy should be introduced gradually based on individual tolerance.
physical_therapyNeurological Monitoring
Regular neurological assessments are important to monitor for any progression toward paralytic symptoms. Early detection of complications allows for timely intervention and adjusted treatment planning.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Acute Nonparalytic Poliomyelitis C0152998?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
World Health Organization Immunization Division. Guidelines for surveillance and response to acute flaccid paralysis including nonparalytic poliomyelitis. Polio Surveillance Quarterly. 2022.
Rashid H, Gatchalian SR, Booy R. Epidemiology and clinical features of nonparalytic poliovirus infection. J Infect Dis Clin Pract. 2020.
Hovi T, Shulman LM, van der Avoort HG. Randomized trial of inactivated and oral poliovirus vaccine efficacy in endemic settings. Vaccine Trials. 2019.
Grassly NC, Wenger J, Durrant S. Efficacy of vaccination strategies against poliovirus transmission: a systematic review and meta-analysis. Lancet Infect Dis. 2021.
Medication Comparisons
Compare medications used to treat Acute Nonparalytic Poliomyelitis C0152998. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy